Audentes Therapeutics Inc (BOLD) PT Set at $24.00 by Piper Jaffray Cos.
Audentes Therapeutics Inc (NASDAQ:BOLD) has been given a $24.00 price target by investment analysts at Piper Jaffray Cos. in a research note issued to investors on Monday. The brokerage presently has a a “buy” rating on the stock. Piper Jaffray Cos.’s price objective points to a potential upside of 30.86% from the company’s previous close.
Other research analysts also recently issued research reports about the company. Wedbush restated an “outperform” rating and issued a $20.00 target price on shares of Audentes Therapeutics in a research note on Thursday, September 1st. Cowen and Company started coverage on Audentes Therapeutics in a research note on Monday, August 15th. They issued an “outperform” rating on the stock.
Shares of Audentes Therapeutics (NASDAQ:BOLD) traded up 1.80% during midday trading on Monday, hitting $18.67. The stock had a trading volume of 13,767 shares. The firm’s market cap is $405.61 million. Audentes Therapeutics has a 12-month low of $13.06 and a 12-month high of $19.26. The firm has a 50-day moving average of $15.80 and a 200 day moving average of $15.45.
In related news, major shareholder Versant Ventures Iv, Llc purchased 35,000 shares of the firm’s stock in a transaction dated Monday, July 25th. The stock was bought at an average price of $15.00 per share, for a total transaction of $525,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider James E. Flynn purchased 400,000 shares of the firm’s stock in a transaction dated Monday, July 25th. The shares were bought at an average price of $15.00 per share, with a total value of $6,000,000.00. The disclosure for this purchase can be found here.
About Audentes Therapeutics
Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Stock Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related stocks with our FREE daily email newsletter.